Table 1.
Albiglutide Monotherapy versus Placebo: Results at Week 52
| Efficacy parameter | Placebo (N = 99) |
Albiglutide 30 mg weekly (N = 100) |
Albiglutide 50 mg weekly (N = 97) |
|---|---|---|---|
| HbA1c level | |||
| Baseline, mean, % | 8.0 | 8.1 | 8.2 |
| Change at week 52, % | +0.2 | −0.7 | −0.9 |
| Difference from placebo, % | −0.8 (95% CI, −1.1 to −0.6)a | −1.0 (95% CI, −1.3 to −0.8)a | |
| Patients achieving HbA1c <7%, % | 21 | 49 | 40 |
| Fasting plasma glucose | |||
| Baseline, mean, mg/dL | 163 | 164 | 171 |
| Change at week 52, mg/dL | +18 | −16 | −25 |
| Difference from placebo, mg/dL | −34 (95% CI, −46 to −22)a | −43 (95% CI, −55 to −31)a | |
a
P <.001.
CI indicates confidence interval; HbA1c, glycated hemoglobin.
Source: Tanzeum (albiglutide) for injection prescribing information; April 2014.